DBV Technologies Initiates COMFORT Toddlers Phase 3 Study for Viaskin Peanut Patch in Young Children
DBV Technologies has begun screening the first subject in its COMFORT Toddlers Phase 3 supplemental safety study, evaluating the Viaskin Peanut patch 250 μg in peanut-allergic children ages 1-3 years old.
Isomorphic Labs Secures $600M to Advance AI-Powered Drug Discovery Platform
Isomorphic Labs raised $600 million in its first external funding round in March 2025, representing the largest private biotech investment of the month.
Viaskin Peanut Patch Shows Promise in Toddlers with Peanut Allergy, Gains FDA Accelerated Approval Pathway
DBV Technologies' Viaskin Peanut patch demonstrates sustained benefits over 36 months in toddlers aged 1-3, improving treatment efficacy and safety.
DBV Technologies Advances Viaskin Peanut Patch with FDA and EMA Support
DBV Technologies gains FDA agreement for Accelerated Approval of Viaskin Peanut patch in toddlers aged 1-3, pending a supplemental safety study.
DBV Technologies Concludes VITESSE Trial Screening for Viaskin Peanut Patch
DBV Technologies completed screening for its VITESSE Phase 3 trial, surpassing recruitment goals for peanut-allergic children aged 4-7.
Viaskin Peanut Allergy Patch Shows Promise in Toddlers
A clinical trial reveals that a skin patch, Viaskin, significantly increases peanut tolerance in toddlers with peanut allergies.